2016 American Transplant Congress
Proteoforms: Novel Biomarkers for Acute Rejection in Liver Transplant Recipients.
1Northwestern, Chicago; 2UPMC, Pittsburgh.
Background: Biomarker profiles diagnostic of acute rejection (AR) in liver transplant (LT) recipients could enhance the diagnosis and management of recipients. Our aim was to…2016 American Transplant Congress
Enhanced Activation of Hemostasis During Kidney Transplantation in Patients on Dialysis Compared to Pre-Emptively Transplanted Patients.
Groningen Transplant Center, University Medical Center Groningen, Groningen, Netherlands.
Introduction: It is generally assumed that dialysis patients (DP) have a more severe bleeding diathesis related to platelet dysfunction than pre-emptively transplanted patients (PEP) who…2016 American Transplant Congress
Antithymocyte Globulin (ATG) versus Anti-interleukin-2 Receptor (Anti-IL-2R) as Induction Therapy for Kidney Transplantation After a Nonrenal Transplant.
Patients undergoing kidney transplant after a previous nonrenal organ transplant (NRT) present a small but emerging subpopulation of kidney transplant recipients. Little is known about…2016 American Transplant Congress
C5a Induces CSF1-Dependent Regulatory Macrophage (Mreg) Development Required for Murine Allograft Tolerance.
Icahn School of Medicine at Mount Sinai, New York, NY.
Anti-CD40L (MR1) induced heart transplant tolerance has been recently shown to be dependent on early post-transplant intragraft accumulation of CD11b+Ly6CLoLy6G- DC-SIGN expressing Mreg that develop…2016 American Transplant Congress
Delayed Induction of Mixed Chimerism Permits Kidney-Induced Cardiac Allograft Tolerance to be Applied to Recipients of Cadaveric Organs.
(BACKGROUND)Cardiac tolerance in nonhuman primates (NHPs) has been induced for the first time by kidney co-transplantation in combination with donor bone marrow infusion when the…2016 American Transplant Congress
Avoidance of CNI and Steroids Using Belatacept – A Preliminary Report of CTOT-16.
1UAB, Birmingham; 2UCSF, San Francisco; 3Emory, Atlanta; 4Rho, Chapel Hill; 5NIAID, Bethesda.
CTOT-16 tested the hypothesis that belatacept used as maintenance immunosuppression (IS) in kidney transplantation would allow the long-term avoidance of CNI and corticosteroids. Methods: Primary…2016 American Transplant Congress
Understanding the Initial Rise in Kidney Discard Rates Observed Post-KAS.
1UNOS, Richmond, VA; 2Emory Univ, Atlanta, GA; 3Univ Hosp Case Med Ctr, Cleveland, OH.
Background: Kidney discard rates increased by 10% -- from 18.3% to 20.2% (p=0.001) -- during the first 7 months of KAS but returned to pre-KAS…2016 American Transplant Congress
Investigating Posttransplant Allo-Donor Specific CD57+ Cells in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.
Department of Surgery, Duke University, Durham, NC.
Recent studies have showed correlation between CD4+CD57+PD1- cells and costimulation blockade resistant rejection (CoBRR) in patients treated with belatacept without depletional induction. We have recently…2016 American Transplant Congress
Pulse Pressure and GFR Decay in Kidney Transplant Recipients.
Single blood pressure values have commonly been used to assess the risk of allograft failure in kidney transplant recipients. In this analysis we prospectively evaluated…2016 American Transplant Congress
A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.
1Emory Transplant Center, Atlanta, GA; 2Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 180
- Next Page »